The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemotherapy randomization.
 
Karen Basen-Engquist
No Relationships to Disclose
 
Helen Q Huang
No Relationships to Disclose
 
Thomas J Herzog
No Relationships to Disclose
 
Deborah Kay Armstrong
Consulting or Advisory Role - Eisai (I); eviti; Morphotek
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (I); Exelixis (I); Genentech (Inst); Ventirx (Inst)
 
Paul Sabbatini
Research Funding - Janssen Oncology (Inst); OncoMed (Inst)
 
Joan L. Walker
No Relationships to Disclose
 
Byoung Gie Kim
No Relationships to Disclose
 
Keiichi Fujiwara
Honoraria - Chugai Pharma; Eisai; Kyowa Hakko Kirin; Nippon Kayaku; Taiho Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - Arno Therapeutics; Chugai Pharma; GlaxoSmithKline
Research Funding - Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Krishnansu Sujata Tewari
No Relationships to Disclose
 
David M. O'Malley
Consulting or Advisory Role - Eisai; Janssen Oncology
Research Funding - Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Immunogen (Inst); Janssen Research & Development (Inst); Regeneron (Inst); VentiRx (Inst)
 
Robert L. Coleman
Honoraria - NCCN
Consulting or Advisory Role - Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche
Research Funding - Amgen; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merrimack; OncoMed
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Gradalis; Merck; Merrimack; Millennium